報價延遲最少15分鐘:2026/08/01 11:09 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
-- 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.83/--
|
|
企業價值
482.07M
|
| 資產負債 |
|
每股賬面淨值
3.56
|
| 現金流量 |
|
現金流量率
0.12
|
| 損益表 |
|
收益
386.01M
|
|
每股收益
3.23
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Sinovac Biotech Ltd is a fully integrated China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of vaccines for the prevention of human infectious diseases, including certain diseases with unmet medical needs. It has developed a comprehensive vaccine portfolio covering hepatitis A, hepatitis B, hand, foot and mouth disease ("HFMD") caused by enterovirus 71 ("EV71"), seasonal and pandemic influenza, COVID-19, pneumococcal disease, poliomyelitis, mumps, varicella, rabies and tetanus. The Company operates exclusively in the research, development, manufacture, and commercialization of vaccines sector. The Company's business is considered as operating in onesegment. It has presence in Chinese Mainland, and Outside Chinese Mainland. |
